Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sagimet Biosciences Inc. filings document a clinical-stage biopharmaceutical issuer with Series A common stock listed on the Nasdaq Global Market and emerging growth company status. Recent 8-K reports cover financial results, preliminary financial information, Regulation FD investor presentations, a material underwriting agreement and related capital-structure disclosures, and executive leadership changes.
The company’s proxy materials describe annual meeting voting matters, stockholder procedures, board-related items, and governance proposals. Its disclosures also track use-of-proceeds language, clinical-development updates for FASN inhibitor programs, and public-company reporting matters.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek sold 10,545 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.7603 per share in transactions between $7.76 and $7.88.
The report states that these shares were automatically sold to cover tax withholding obligations related to vesting restricted stock units and were not at Rozek’s discretion. After these sales, she directly holds 224,414 shares of Sagimet stock.
George Kemble, a director of Sagimet Biosciences Inc., sold 18,844 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.4575 per share in open-market or private transactions under a Rule 10b5-1 trading plan adopted on August 21, 2025. After these sales, he directly holds 62,161 shares. The reported trades occurred at prices ranging from $7.17 to $7.97 per share.
Sagimet Biosciences Inc. furnished an updated investor presentation describing its strategy around fatty acid synthase (FASN) inhibition in dermatology and metabolic disease. Lead oral FASN inhibitor denifanstat showed proof-of-concept in multiple settings, including a Phase 3 acne trial in China that met all primary and secondary endpoints and supported a denifanstat new drug application accepted by the China NMPA in December 2025.
The company plans a US Phase 3 trial of denifanstat in moderate to severe acne in the second half of 2026, contingent on regulatory consultation, and highlights a completed Phase 2b trial in MASH that met histology primary and multiple secondary endpoints and received FDA Breakthrough Therapy designation. Follow-on FASN inhibitor TVB-3567 is in a first-in-human Phase 1 study begun June 2025, with a Phase 2 acne trial anticipated in 2026, subject to regulatory feedback.
Sagimet reports intellectual property coverage for denifanstat and TVB-3567 extending into the 2030s and beyond. It cites $104 of cash, cash equivalents and marketable securities as of March 31, 2026 and an announced $175M underwritten Series A common stock offering in April 2026, which together are expected to fund operations through 2028 and through the planned denifanstat US Phase 3 acne readout.
Sagimet Biosciences director Beth C. Seidenberg received a grant of stock options covering 39,567 shares of Series A common stock on June 12, 2026. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
These options were awarded as a compensation grant, not a market purchase or sale. According to the terms, the underlying shares will vest in twelve equal monthly installments after June 12, 2026, as long as she continues serving the company on each vesting date.
Sagimet Biosciences Inc. director Paul W. Hoelscher received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
The award was granted at no cost to him and is structured as compensation, not an open-market trade. The underlying 39,567 shares will vest in twelve equal monthly installments beginning on June 12, 2026, subject to his continued service.
Sagimet Biosciences Inc. director Jennifer Jarrett reported a grant of stock options on Series A Common Stock. She received options for 39,567 shares at an exercise price of $6.48 per share, all held as a direct derivative position following the transaction.
According to the terms, the shares underlying this option will vest and become exercisable in twelve equal monthly installments following June 12, 2026, conditioned on her continued service on each vesting date. The option expires on June 11, 2036, providing a long-dated equity incentive aligned with her board role.
Sagimet Biosciences Inc. director Elizabeth A. Grammer received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
The shares underlying this option are scheduled to vest in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. This is a compensation-related award and does not reflect any open-market buying or selling of Sagimet stock.
Sagimet Biosciences Inc. granted director Kemble George a stock option covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. The option expires on June 11, 2036 and represents 39,567 derivative shares held after this grant.
According to the award terms, the shares underlying this option vest in twelve equal monthly installments following June 12, 2026, conditioned on his continued service on each vesting date.
Sagimet Biosciences Inc. director Anne M. Phillips received a grant of stock options covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. These options were awarded as compensation and are held directly.
The options vest and become exercisable in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. Following this grant, she holds stock options for 39,567 underlying shares, all from this award.